Complement blockade with eculizumab for treatment of severe Coronavirus Disease 2019 in pregnancy: A case series

PROBLEM: We evaluated eculizumab, a complement protein C5 inhibitor, for treatment of severe COVID‐19 in pregnant and postpartum individuals. METHOD OF STUDY: Protocol ECU‐COV‐401 (clinicaltrials.gov NCT04355494) is an open label, multicenter, Expanded Access Program (EAP), evaluating eculizumab for...

Descripción completa

Detalles Bibliográficos
Autores principales: Burwick, Richard M., Dellapiana, Gabriela, Newman, Rachel A., Smithson, Sarah D., Naqvi, Mariam, Williams, John, Wong, Melissa S., Bautista, Martha, Gaden, Anna, Kazani, Shamsah D., Dunn, Derek A., Ma, Mark H., Mitter, Sanjay, Monteleone, Jonathan P. R., Ortiz, Stephan R., Ghandehari, Sara, Merin, Noah, Zakowski, Mark I., Karumanchi, S. Ananth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Clinical Reproductive Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9347938/
https://www.ncbi.nlm.nih.gov/pubmed/35514201
http://dx.doi.org/10.1111/aji.13559

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9347938/
https://www.ncbi.nlm.nih.gov/pubmed/35514201
http://dx.doi.org/10.1111/aji.13559

Ejemplares similares